- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04890574
CellMist™ Autologous Cells to Treat Deep Second-Degree Burns (CELLMIST1)
An Open Label Pilot Study to Evaluate the CellMist™ System in the Treatment of Deep Second Degree (IIoB) Burn Injuries With Autologous Skin Cells
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients between the ages of 18 and 65 years of age inclusive with a ≤ 30% Total Body Surface Area (TBSA) that requires surgical or enzymatic debridement and split thickness skin grafting (STSG) on any body surface excluding the face, joints, perineum and hands will be considered for participation in this study. CellMist™ solution (autologous epidermal and dermal cells) will be administered, via the System Skin Gun™, will be evenly distributed to aid in burn healing. Healing, pain and treatment-related adverse events will be evaluated at follow-up visits. Data concerning safety of the CellMist™ System will be collected. Safety will be evaluated in terms of treatment and serious related adverse events.
Each subject will participate in up to 9 total visits (screening, treatment and 7 follow-up study visits) over a period of 52 weeks. Up to 14 subjects will be enrolled and treated within this at up to 4 institutions.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington MedStar Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is between 18 and 65 years of age inclusive;
- Has at least one discrete deep second degree (II°B) thermal burn injury (≤ 30% Total Body Surface Area (TBSA)) that requires surgical or enzymatic debridement and split thickness skin grafting (STSF) on any body surface excluding the face, joints, perineum and hands;
- Agrees to abstain from any other surgical treatment of the wound(s) for the duration of the study unless determined by the Principal Investigator to be medically necessary;
- Treatment with CellMist™ occurs with 7 days of burn injury;
- Demonstrates (as determined by the Principal Investigator) the ability and willingness to follow the requirements of the protocol;
- Understand the full nature and purpose of the study and provides voluntary written informed consent -
Exclusion Criteria:
- Is pregnant or does not agree to use acceptable contraception methods for the duration of their participation in the clinical trial (latter applies to women and men of child bearing potential);
- Is breast feeding;
- Has a pre-existing local and/or systemic bacterial infection that requires antibiotic treatment for more than 2 days prior to study treatment;
- Demonstrates an anesthesia risk that (as determined by the Principal Investigator) prohibits treatment
- Body Mass Index (BMI) ≥ 39;
- The burn(s) at the target treatment area(s) results from chemical, electrical or radiation exposure;
- Has full thickness (III°) burns TBSA ≥ 20%
- Has comorbidities and/or medications and/or health status that (as determined by the Principal Investigator) could result in poor cell isolation and/or poor wound healing (e.g., uncontrolled and/or significant diabetes (≥8% HbA1c by medical record), peripheral vascular disease, active malignancy or treatment (other than surgery) of malignancy within the past 3 months, autoimmune disease, renal failure (glomerular filtration rate <60mL/minute) and/or systemic steroid usage);
- Known hypersensitivities to trypsin, collagenase, or GentLyase (dispase);
- Has a medical condition that would make life expectancy < 12 months;
- Is currently participating in another prospective investigational clinical trial;
- Does not agree to abstain from enrolling in any other study for the duration of this study;
- Gram staining of SkinGun™ cell suspension output shows excessive microbial bioburden (≥ 200 microbial particles/field)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Adverse Events
Time Frame: We will be evaluating all adverse events reported for the period from enrollment through the final visit which will be 12 months
|
All Adverse Events will be reported, recorded and analyzed which occur from the time Informed Consent is given through the conclusion of the study.
We will be looking at ; Incidence, Severity, Expectedness, Duration, Treatment, and the Relationship to Device for each Adverse Event reported.
|
We will be evaluating all adverse events reported for the period from enrollment through the final visit which will be 12 months
|
Secondary Surgical Interventions
Time Frame: The evaluation will include all reported secondary surgical interventions for the period from enrollment and up to 12 months
|
We will be evaluating and analyzing all secondary surgical interventions required to treat the intended target wound.
A secondary surgical intervention may include debridement, biopsy, identification of an infectious pathogen, split thickness skin graft, etc...
|
The evaluation will include all reported secondary surgical interventions for the period from enrollment and up to 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC12302017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
Sun Yat-sen UniversityCompleted
-
MediWound LtdActive, not recruitingThermal BurnsUnited States, United Kingdom, Spain, Georgia, Belgium, Poland, Germany, Hungary, India, Italy, Netherlands, Romania, Slovakia, Ukraine
-
Virginia Commonwealth UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityCompleted
-
St. Justine's HospitalRecruiting
-
Yingfeng ZhengCompleted
Clinical Trials on CellMist™ System
-
Medtronic CardiovascularMedtronicCompletedAortic StenosisNew Zealand, United Kingdom, Australia
-
Boston Scientific CorporationWithdrawnMultiple Pulmonary Nodules | Solitary Pulmonary Nodule | Biopsy, Fine-NeedleUnited States
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...RecruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
Medtronic CardiovascularActive, not recruitingAortic Valve StenosisNetherlands, France, Italy, Germany, Spain, Denmark, Belgium, United Kingdom, Slovenia, Finland, Austria, Israel, Norway, Switzerland
-
Northwell HealthTerminatedStroke | Stroke Sequelae | Hemiparesis | Hemiplegia, Spastic | CVA | Spasticity as Sequela of Stroke | Upper Limb HypertoniaUnited States
-
Kantonsspital Winterthur KSWAbbott; Cantonal Hospital of St. GallenActive, not recruitingPeripheral Arterial DiseaseSwitzerland, Spain
-
Medtronic CardiovascularActive, not recruitingAortic AneurysmGermany, New Zealand, United States, Netherlands, Switzerland, United Kingdom, Spain, Australia, Italy, Sweden, France, Austria, Slovakia
-
Encore Medical, L.P.TerminatedRheumatoid Arthritis | Traumatic Arthritis | Joint Disease Secondary to OsteoarthritisUnited States
-
LifeBridge HealthOrthosensor, Inc.WithdrawnDegenerative ArthritisUnited States
-
Neo Medical SAConfinisCPMActive, not recruitingTrauma | Degenerative Disc Disease | Spinal Stenosis | Spondylolisthesis | Spinal Tumor | Pseudoarthrosis of SpineGermany, Spain